Welcome to our dedicated page for Elevation Oncology news (Ticker: $ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elevation Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elevation Oncology's position in the market.
Elevation Oncology, Inc. (Nasdaq: ELEV) will have its CEO, Joseph J. Ferra, participate in a fireside chat at the Citizens JMP Life Sciences Conference on May 14, 2024. The company focuses on developing cancer therapies for solid tumors with unmet medical needs.
Elevation Oncology, Inc. reported its first-quarter 2024 financial results, highlighting recent business achievements. The company raised $44.2 million year-to-date through an ATM facility, extending its cash runway into 2026. Enrollment in the Phase 1 clinical trial of EO-3021 is ongoing in the U.S. and Japan, with initial safety and efficacy data expected by mid-3Q 2024. Preclinical proof-of-concept data for the HER3-ADC program was presented at the AACR Annual Meeting, with the company on track to nominate a development candidate in 2H 2024.